The BCL-2 Inhibitor Venetoclax Augments Immune Effector Function Mediated by Fas Ligand, TRAIL, and Perforin/Granzyme B, Resulting in Reduced Plasma Viremia and Decreased HIV Reservoir Size during Acute HIV Infection in a Humanized Mouse Model

The BCL-2 prosurvival protein is implicated in HIV persistence and is a potential therapeutic target for HIV eradication efforts. We now know that cells harboring HIV are preferentially enriched for high BCL-2 expression, enabling their survival, and that the BCL-2 inhibitor venetoclax promotes the...

Descripción completa

Detalles Bibliográficos
Autores principales: Chandrasekar, Aswath P., Cummins, Nathan W., Natesampillai, Sekar, Misra, Anisha, Alto, Alecia, Laird, Greg, Badley, Andrew D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Vaccines and Antiviral Agents
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9769373/
https://www.ncbi.nlm.nih.gov/pubmed/36448802
http://dx.doi.org/10.1128/jvi.01730-22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9769373/
https://www.ncbi.nlm.nih.gov/pubmed/36448802
http://dx.doi.org/10.1128/jvi.01730-22

Ejemplares similares